Revolution Medicines, Inc. (NASDAQ:RVMD) Q1 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Revolution Medicines Q1 2025 Earnings Conference Call.
Revolution Medicines Inc. (RVMD)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Farallon Capital Thomas Steyer | 13,534,692 | $478,586,709 | +3% | 2.67% |
| 2. | Baker Bros. Advisors Julian Baker And Felix Baker | 7,936,972 | $280,651,330 | 3.11% | |
| 3. | Biotechnology Value Fund / BVF Inc Mark Lampert | 4,982,384 | $176,177,098 | +20% | 7.18% |
| 4. | Woodline Partners Michael Rockefeller And Karl Kroeker | 3,887,036 | $137,445,593 | +1% | 0.89% |
| 5. | Casdin Capital Eli Casdin | 3,697,933 | $130,758,911 | -1% | 10.68% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $46.00 | 760,869 | 760,869 | 2024-12-05 | Filing | ||
| $46.00 | 543,478 | 2,096,612 | 2024-12-05 | Filing | ||
| $20.85 | 6,200 | Director | 1,553,134 | 2023-03-10 | Filing | |
| $20.43 | 93,800 | Director | 1,546,934 | 2023-03-10 | Filing | |
| $22.00 | 318,181 | Director | 618,181 | 2023-03-07 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $38.71 | 2,041 | 57,723 | 2025-03-20 | Filing | ||
| $39.04 | 1,458 | 59,764 | 2025-03-17 | Filing | ||
| $39.04 | 11,738 | 441,564 | 2025-03-17 | Filing | ||
| $39.04 | 1,864 | 115,006 | 2025-03-17 | Filing | ||
| $39.04 | 3,058 | 153,533 | 2025-03-17 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 16,612,035 | $587,401,558 | 0.01% | |
| 2. | 14,692,392 | $519,522,981 | 0.01% | |
| 3. | 11,787,921 | $416,820,887 | 0.08% | |
| 4. | 10,190,071 | $380,566,792 | 0.21% | |
| 5. | 7,601,087 | $268,774,436 | 62.46% |
News See All
10 Best Debt Free Mid Cap Stocks to Buy Now
Debt-free mid-cap stocks currently offer compelling investment opportunities, especially in today's high-interest-rate environment.
10 Best Mid Cap Biotech Stocks to Buy
On March 6, Jared Holz, Mizuho health care equity strategist, appeared on CNBC's 'Power Lunch' to discuss investing in biotech and the oversaturation in the sector.
10 Cash-Rich Mid Cap Stocks To Buy Now
Cash flow is the money moving in and out of a business over a set period. It is important because it shows how much cash a company actually has on hand, rather than just looking at profits on paper.
Revolution Medicines, Inc. (NASDAQ:RVMD) Q4 2024 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Revolution Medicines Q4 2024 Earnings Conference Call.
12 Best Healthcare Stocks to Buy According to Analysts
McKinsey reported that, since 2019, the US healthcare industry witnessed significant financial pressure.
10 Best Russell 2000 Stocks to Invest in According to Analysts
The Russell 2000 Index is a widely followed benchmark that tracks the performance of small-cap companies in the United States.
12 Biotech Stocks with the Biggest Upside Potential
While 2024 was a "challenging" year for biotech stocks, JPMorgan is of the view that some names in the industry may be poised for considerable upside in the coming months.
Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2024 Earnings Call Transcript
Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2024 Earnings Call Transcript November 6, 2024Revolution Medicines, Inc. misses on earnings expectations.
10 Largest Biotech Hedge Funds and Their Top Stock Picks
The ability to successfully make money through investment requires deep thinking and analysis.
Billionaire Hedge Funds
